RxDoctor Payments Data

Matthew Harris, MD

Internal Medicine · Clarkston, MINPI 1154314029

Payments from drug & device makers

$8,591in general payments, 2019–2025

Across 526 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$1K
  • Novo Nordisk$773
  • Amgen$651
  • AbbVie$606
  • Lilly USA, LLC$551
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$8,585100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,591 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$126,070
Medicare patients
253
Services billed
12,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin220$219,400
EliquisApixaban197$186,303
Trelegy ElliptaFluticasone/Umeclidin/Vilanter220$170,385
MounjaroTirzepatide74$122,019
FarxigaDapagliflozin Propanediol115$96,557
OzempicSemaglutide58$82,048
TrulicityDulaglutide41$68,529
JanuviaSitagliptin Phosphate56$48,976
XareltoRivaroxaban34$42,660
ProliaDenosumab23$38,889
MyrbetriqMirabegron54$35,371
EntrestoSacubitril/Valsartan28$34,524
RybelsusSemaglutide19$33,271
Bydureon BciseExenatide Microspheres24$31,055
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$29,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$389$219,400220 claims
Lilly USA, LLCMounjaro, Trulicity$551$190,548115 claims
PfizerEliquis$380$186,303197 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,428$179,241232 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$1,110$143,707179 claims
Novo NordiskOzempic, Rybelsus$773$115,31877 claims
MerckJanuvia$65$48,97656 claims
Johnson & JohnsonXarelto$132$42,66034 claims
AmgenProlia$651$38,88923 claims
Astellas Pharma US IncMyrbetriq$74$35,37154 claims
NovartisEntresto$267$34,52428 claims
AbbVieLinzess$606$14,09422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Clarkston

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →